Company: DNLI
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0001714899-25-000170
Chunk: 184

Company: Denali Therapeutics Inc.
Filing Date: 2025-08-11
Form: 10-Q
Item: Part I, Item 1
Chunk 184
---
 (Loss)Accumulated DeficitTotal Stockholders' EquitySharesAmountBalance at December 31, 2024144,220,986 $1,768 $2,764,880 $2,020 $(1,538,984)$1,229,684 Issuances under equity incentive plans455,335 5 4,647 — — 4,652 Vesting of restricted stock units1,009,121 10 (10)— — — Stock-based compensation— — 50,887 — — 50,887 Net loss— — — — (257,089)(257,089)Other comprehensive loss— — — (1,081)— (1,081)Balance at June 30, 2025145,685,442 $1,783 $2,820,404 $939 $(1,796,073)$1,027,053 Balance at March 31, 2025145,251,258 $1,778 $2,790,825 $2,037 $(1,671,954)$1,122,686 Issuances under equity incentive plans341,543 4 4,053 — — 4,057 Vesting of restricted stock units92,641 1 (1)— — — Stock-based compensation— — 25,527 — — 25,527 Net loss— — — — (124,119)(124,119)Other comprehensive loss— — — (1,098)— (1,098)Balance at June 30, 2025145,685,442 $1,783 $2,820,404 $939 $(1,796,073)$1,027,053 Balance at December 31, 2023138,385,498 $1,711 $2,144,811 $643 $(1,116,211)$1,030,954 Issuance of common stock and pre-funded warrants, net of issuance costs of $4803,244,689 32 499,221 — — 499,253 Issuances under equity incentive plans657,522 7 7,771 — — 7,778 Vesting of restricted stock units835